Showing results (2121-2130 of 2,152) with videos related to

Sort By:
Pageof 216
Nature Communications|April 2, 2022
Defining the early stages of intestinal colonisation by whipwormsMaría A Duque-Correa, David Goulding, Faye H Rodgers, et al.
Canadian Journal of Microbiology|March 3, 2025
Molecular epidemiology and in silico prediction of ciprofloxacin resistance in Salmonella enterica in Canada, 2017-2022MacKenzie A P Wilke, Ketna Mistry, David Thumbi, et al.
Journal of Pineal Research|August 19, 2024
A Protocol to Determine Circadian Phase by At-Home Salivary Dim Light Melatonin Onset AssessmentJade M Murray, Julia E Stone, Sabra M Abbott, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 20, 2018
Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's EsophagusJing Dong, David M Levine, Matthew F Buas, et al.
Journal of Biomedical Science|October 3, 2020
Endothelin receptor antagonist improves donor lung function in an ex vivo perfusion systemK Walweel, K Skeggs, A C Boon, et al.
Medical Care Research and Review : MCRR|October 30, 2016
Implementation of Care Management: An Analysis of Recent AHRQ ResearchAndrada Tomoaia-Cotisel, Timothy W Farrell, Leif I Solberg, et al.
Gastroenterology|December 17, 2017
Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic VariantsJing Dong, Matthew F Buas, Puya Gharahkhani, et al.
Rheumatology Advances in Practice|October 15, 2025
Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scopeStephanie F Ling, Joshua L Bennett, Vanessa J Reid, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 4, 2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancerRobert W Holloway, Premal Thaker, Alberto A Mendivil, et al.
Journal of the National Cancer Institute|October 31, 2013
Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal refluxWeronica E Ek, David M Levine, Mauro D'Amato, et al.
Pageof 216